説明
Safety and adverse event data from the probiotic supplementation trial confirm the tolerability of Lactiplantibacillus plantarum GTB1 at the administered dose.
Figure 7
ChartSource Paper
Effect of Oral Intake of Lactiplantibacillus plantarum APsulloc 331261 (GTB1TM) on Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Study.Cite This Figure
![Figure 7: Safety and adverse event data from the probiotic supplementation trial confirm the tolerability of Lactiplantibacillus plantarum GTB1 at the administered dose.]() > Source: Kyoungmi Jung et al. "Effect of Oral Intake of Lactiplantibacillus plantarum APsulloc 331261 (GTB1TM) ." *Nutrients*, 2022. PMID: [35631156](https://pubmed.ncbi.nlm.nih.gov/35631156/)
<figure> <img src="" alt="Safety and adverse event data from the probiotic supplementation trial confirm the tolerability of Lactiplantibacillus plantarum GTB1 at the administered dose." /> <figcaption>Figure 7. Safety and adverse event data from the probiotic supplementation trial confirm the tolerability of Lactiplantibacillus plantarum GTB1 at the administered dose.<br> Source: Kyoungmi Jung et al. "Effect of Oral Intake of Lactiplantibacillus plantarum APsulloc 331261 (GTB1TM) ." <em>Nutrients</em>, 2022. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/35631156/">35631156</a></figcaption> </figure>